Genialis’ Post

Happy July everyone, I hope we are all gearing up for some celebrations tomorrow 🎆 but in the mean time here is Biotech Company showcase #5 Gero 🌟 Gero is a preclinical-stage target & drug discovery company creating therapeutics for age-related diseases. Gero applies machine learning algorithms originating from the physics of complex systems to build clinically relevant disease progression models in real-world human data. Then we use molecular data such as Whole-Exome sequencing (or plasma proteomics) to RWD-based protective variants - therapeutic targets - potentially applicable to several indications simultaneously. The in-human drug discovery approach allows us to avoid the “preclinical trap” and select the most efficient targets against human (not mice) diseases. Gero has an active collaboration with Pfizer and their research has been published in Nature Communications and Science journals as well as covered by Scientific American and Popular Mechanics. ⭐ Whether you know Gero through their appearances at a conferences, their collaboration with Pfizer, multiple publications or even their shout out from the total 69 million follower social media pages Ladbible, Gero is becoming one of the best known names in the industry. We look forward to seeing you there Alexey Kadet #lsxusa #biotech #techbio #ai #investment #partnering

🌟 Exciting News in Drug Discovery! 🌟 Thrilled to share the publication of groundbreaking research titled "A small-molecule TNIK inhibitor targets fibrosis in preclinical and clinical models" in Nature Biotechnology by Alex Zhavoronkov and the team at Insilico Medicine! 🔬 Leveraging cutting-edge AI technology, Alex Zhavoronkov and the Insilico Medicine team identified and TNIK as a promising anti-fibrotic target, paving the way for innovative therapeutic interventions. Key highlights: 1️⃣ Utilization of AI to discover TNIK as an anti-fibrotic target. 2️⃣ "Hallmarks of aging assessment" revealed promising results for TNIK. 3️⃣ Innovative molecule design using Chemistry42 AI for enhanced safety and efficacy. 4️⃣ Extensive in vitro and in vivo experiments leading preclinical candidates for lung and kidney fibrosis. 5️⃣ Successful completion of a clinical safety trial in humans. Excitingly, the paper is easily accessible for questions through the chat feature at https://lnkd.in/gzm3FaMW, and a comprehensive data repository is available at https://lnkd.in/gudR2pZN. 🌐 Explore recent publications and collaborations by Alex and Insilico, and dive into the therapeutic pipeline propelled by generative platforms. Read the full paper here: https://lnkd.in/epYVmPgf #Biotechnology #Innovation #AI #FibrosisResearch #TherapeuticDevelopment #NatureBiotechnology #ResearchBreakthroughs

🔬 𝗔𝗰𝗰𝗲𝗹𝗲𝗿𝗮𝘁𝗲 𝘆𝗼𝘂𝗿 𝗿𝗲𝘀𝗲𝗮𝗿𝗰𝗵 𝗷𝗼𝘂𝗿𝗻𝗲𝘆 𝘄𝗶𝘁𝗵 𝗡𝗮𝗻𝗼𝗹𝗶𝘃𝗲! 🚀 https://bit.ly/3SXzfMK Welcome to our new members, we are thrilled to have you on board! Allow us to introduce Nanolive, where cutting-edge science meets innovation. Nanolive delivers breakthrough 3D imaging solutions that accelerate research in growth industries such as drug discovery and cell therapy. Nanolive’s innovative solutions combine imaging and analysis to radically advance how scientists study living cells and provide novel biological insights, such as the mechanisms of cancer and unique cellular phenotypes. Experience our 3D Cell Explorer 96focus, an automated label-free live cell imaging solution. Unlock unlimited high content analysis through AI-powered digital assays. Trust Nanolive to revolutionize your lab time, enabling in-depth exploration of living cells, from drug discovery to preclinical toxicity and safety testing. #biotechnology #science #nanolive #medtech #cellimaging #research #innovation

LucidQuest Strategic Insights (lqventures.com) >>> Gene&Cell Therapy >> Scoop: Resonance Medicine, a protease biotech from David Liu’s lab, shuts down: Resonance Medicine, a two-year-old stealth-stage biotech out of the lab of famed biochemist David Liu, has decided to shut down, Endpoints News has learned. The biotech, backed by some of the industry’s most prominent investors, decided to shut down because the science was too nascent, a source familiar with the matter told Endpoints on Tuesday. Financing, which has been hard to come by in the current biotech environment, was not a reason, the source noted, asking not to be identified. The startup had raised over $50 million, according to the source, with the backing of Atlas Venture, ARCH Venture Partners, F-Prime Capital, GV and Newpath Partners. David Liu The Boston-area biotech was working on technology that would engineer proteases to target specific proteins. The startup had aimed to “revolutionize the treatment of protein-driven diseases,” per an old job posting reported by BioPharma Dive in April. The science was seen as promising but early, with a lot more technical work needed to be done, the source said, adding that Resonance did not have a formal CEO. It’s an abrupt end for a startup from one of the most high-profile entrepreneurs in gene editing. The Broad Institute’s Liu has founded other companies like Editas Medicine, Beam Therapeutics and Prime Medicine. Resonance told employees last Friday that it would shut down. Thomas Cahill Atlas Venture’s Kevin Bitterman, ARCH’s Kristina Burow, GV’s Issi Rozen and F-Prime’s Jessica Alston also serve on the board of Resonance, per company documents. Thomas Cahill is also listed as president of the startup, according to Massachusetts’ corporate documents. Cahill has played an early role in other biotechs like Chroma Medicine, Myeloid Therapeutics and Magnet Biomedicine, among others. More than a dozen biotech startups have folded this year, including neuro-focused genetic medicines upstart Locanabio, non-viral gene therapy maker Intergalactic Therapeutics and Singapore cell therapy biotech Tessa Therapeutics. Endpoints has reached out to Liu and representatives from Newpath, Atlas, GV and F-Prime. #lucidquest #genetherapy #celltherapy

Next week in Boston, Diego Cadavid, our CMO, will join Alexandra Snyder, MD, Najat Khan, PhD, Aparna S., and Rob Brown at Fierce Life Sciences Events' Biotech Summit for a panel that will uncover how #AI is revolutionizing drug discovery and development. Join us to hear how Verge uses human genomics from patient disease tissues and machine learning to develop therapeutics for complex diseases with high unmet need. #FierceBiotechSummit #Biotechnology

Fully automated workflow enabling high-throughput clinical proteomics 👉 Free access at https://lnkd.in/d6MfWcnj (Molecular and Cellular Proteomics, June 2024)   📑 Complex clinical problems sometimes require complex solutions - or at least robots and cutting-edge technology.   📠 In this study led by Anders H. Kverneland, we use liquid chromatography tandem mass spectrometry-based (LC-MS/MS) proteomics with an automated sample preparation to investigate plasma biomarkers to checkpoint inhibitors in patients with metastatic #melanoma.  We found several known and novel regulated proteins associated to progression-free survival.   💡 Complex solutions also require: ✔ Close collaborations, and in this case, the Jesper Velgaard Olsen group at the Novo Nordisk Foundation Center for Protein Research, University of Copenhagen and the biotech company Evosep Biosystems ✔Funding: this work is funded by the Novo Nordisk Foundation, European Research Council (ERC) and Innovation Fund Denmark   #olsengroup #plasmaproteomics #evosepbiosystems #immunotherapy

 What does the future of drug delivery look like? 💊 Yesterday, the VIB Protein Core organized a joint seminar with Waters | Wyatt Technology to tackle that question. At the VIB Protein Core, we attach great importance to these events as biophysics plays a crucial role in protein science. 🔬 We talked about non-viral and viral delivery mechanisms as well as about the acceleration of drug development through high-throughput and automated screening approaches. Also, how do mRNA-based therapeutics feature in the future of medicine? 💡 That future looks bright too. It was great to see such engaged attendees and hear the latest insights into modern drug delivery. Events like this seminar play a pivotal role in fostering collaboration and accelerating the translation of scientific discoveries into transformative therapies. 🚀 #VIB #VIBProteinCore #Biophysics #ProteinScience #DrugDelivery #PharmaceuticalInnovation #ScientificSeminar #Collaboration #mRNATherapeutics Credit to Gunnar De Winter 👏

Targeting Mitochondria 2023 will be dedicated to Professor Vladimir Skulachev: A Tribute to his Vision, Discoveries, and Legacy! A ceremony will be held to honor Prof. Vladimir Skulachev's scientific achievements. Vladimir Gogvadze (Karolinska Institutet) will talk about Prof. Skulachev's strategic impact on #mitochondrialmedicine Maxim Skulachev (CSO at Mitotech S.A.) will share their recent findings from preclinical studies they completed using the latter formulations, Mitotech team successfully harnessed both the antioxidant and mild uncoupling properties of SkQ1 molecule. #WorldMitochondriaSociety #TargetingMitochondria2023 #mitochondria #clinicaltrials #mitochondrialdiseases 

🔬 Thrilled to Present at SynBioBeta 2024! 🔬 Join Cedric Wu, VP of Innovation Center at GenScript USA Inc., on May 7th from 1:45 PM to 2:30 PM in the Grand Ballroom 220A for our session on "Accelerating Revolution in Biotech and BioPharma: The Power of Precision Mutant Libraries." 🧬 Discover the cutting-edge advancements in high-throughput DNA variant libraries that are reshaping protein engineering, target identification, and the development of gene and cell therapies. We'll explore how precision mutant DNA libraries, validated by deep learning models, are unlocking potential in areas like AAV capsids, enhancing tissue organ tropism, and CAR-T therapy design. 🌐 Whether you are involved in biopharma, bioengineering, or genomics, this session will provide a deep dive into the technologies driving rapid advancements in medical research and therapeutic development. Join us! https://lnkd.in/eWR-27hi #SynBioBeta2024 #Biopharma #GenScript #PrecisionHealth

It is great to see #Target2Patient returning to Hinxton Hall Conference Centre next year! I am excited to be involved again. Registration opens 22nd January 2024 for any one working in industry, academia and government, interested in challenging the existing approaches to target selection and translation in drug discovery. Register your interest: https://lnkd.in/exX7t7Uj #scientificconference #conferenceplanning #lifesciences #bigdata